IMM 4.92% 32.0¢ immutep limited

Ann: Promising New Data in 1st line NSCLC from INSIGHT-003 Trial, page-2

  1. 465 Posts.
    lightbulb Created with Sketch. 100
    Announcement is on the ASX market sensitive .... i bought in yesterday at .33 cents...


    Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 TrialEfti plus standard-of-care anti-PD-1 therapy and doublet chemotherapy in 1st line non-small cell lung cancer is well tolerated and continues to show promising initial signals of efficacyTriple combination therapy has achieved a 67% response rate and 91% disease control rate in metastatic 1st line non-small cell lung cancer patients (N=21) despite 81% of patients having low or negative PD-L1 expression

 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
32.0¢
Change
0.015(4.92%)
Mkt cap ! $464.8M
Open High Low Value Volume
30.0¢ 32.5¢ 30.0¢ $1.168M 3.702M

Buyers (Bids)

No. Vol. Price($)
5 148547 32.0¢
 

Sellers (Offers)

Price($) Vol. No.
32.5¢ 51809 2
View Market Depth
Last trade - 16.10pm 24/07/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.